{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-063177","form_type":"8-K","ticker":"TTRX","cik":"0002023016","company_name":"Turn Therapeutics Inc.","filed_at":"2026-06-01T12:45:27+00:00","discovered_at":"2026-06-01T12:50:00.338664+00:00","generated_at":"2026-06-01T12:50:30.453868+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Turn Therapeutics GX-03 Phase 2 interim: 92.6% EASI-50 at 4 weeks; no SAEs","bullets":["92.6% of GX-03 subjects achieved EASI-50 at 4 weeks vs 65.2% vehicle; 70.4% achieved EASI-75.","EASI-90 rates: 44.4% at Week 4 and 51.9% at Week 8 for GX-03 vs 30.4% and 34.8% vehicle.","No treatment-related serious adverse events, tolerability issues, or discontinuations reported.","Enrollment nearing completion; company optimizing trial endpoints and planning FDA meeting.","Detailed data to be presented at Jefferies Global Healthcare conference on June 4, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063177","json":"https://secwatch.observer/filing/0001213900-26-063177.json","markdown":"https://secwatch.observer/filing/0001213900-26-063177.md","text":"https://secwatch.observer/filing/0001213900-26-063177.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2023016/000121390026063177/0001213900-26-063177-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2023016/000121390026063177/ea0292880-8k_turn.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T12:50:30.453868+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001467623-26-000040","ticker":"DBX","company_name":"DROPBOX, INC.","filed_at":"2026-06-01T13:06:23+00:00","headline":"Dropbox secures $400M revolving credit facility, authorizes $900M share repurchase program","event_type":"other_material","sec_items":["1.01","2.03","7.01","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001467623-26-000040","json":"https://secwatch.observer/filing/0001467623-26-000040.json","markdown":"https://secwatch.observer/filing/0001467623-26-000040.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1467623/000146762326000040/0001467623-26-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1467623/000146762326000040/dbx-20260601.htm"},"side_by_side_evidence":null},{"accession":"0001493152-26-026544","ticker":"LIXT","company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","filed_at":"2026-06-01T12:55:34+00:00","headline":"Lixte Biotechnology pivots to AI energy infrastructure; appoints Denham Capital founder to board","event_type":"other_material","sec_items":["5.02","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026544","json":"https://secwatch.observer/filing/0001493152-26-026544.json","markdown":"https://secwatch.observer/filing/0001493152-26-026544.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1335105/000149315226026544/0001493152-26-026544-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1335105/000149315226026544/form8-k.htm"},"side_by_side_evidence":null},{"accession":"0001493152-26-026543","ticker":"BMNR","company_name":"BITMINE IMMERSION TECHNOLOGIES, INC.","filed_at":"2026-06-01T12:45:32+00:00","headline":"Bitmine holds 5.42M ETH (4.49% of supply); total crypto + cash = $11.6B","event_type":"other_material","sec_items":["7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026543","json":"https://secwatch.observer/filing/0001493152-26-026543.json","markdown":"https://secwatch.observer/filing/0001493152-26-026543.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829311/000149315226026543/0001493152-26-026543-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829311/000149315226026543/form8-k.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-249857","ticker":"AIRJ","company_name":"AirJoule Technologies Corp.","filed_at":"2026-06-01T12:34:22+00:00","headline":"AirJoule Technologies raises $15M in registered direct offering at $4.10/share","event_type":"other_material","sec_items":["1.01","5.07","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-249857","json":"https://secwatch.observer/filing/0001193125-26-249857.json","markdown":"https://secwatch.observer/filing/0001193125-26-249857.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855474/000119312526249857/0001193125-26-249857-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855474/000119312526249857/airj-20260528.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-068604","ticker":"NXTC","company_name":"NextCure, Inc.","filed_at":"2026-06-01T12:10:58+00:00","headline":"NextCure Phase 1 SIM0505 data: 55% ORR in gynecologic cancers; cash into Q1 2027","event_type":"other_material","sec_items":["7.01","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068604","json":"https://secwatch.observer/filing/0001104659-26-068604.json","markdown":"https://secwatch.observer/filing/0001104659-26-068604.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661059/000110465926068604/0001104659-26-068604-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661059/000110465926068604/nxtc-20260601x8k.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-063157","ticker":"JSPR","company_name":"Jasper Therapeutics, Inc.","filed_at":"2026-06-01T12:01:20+00:00","headline":"Jasper Therapeutics initiates strategic review including potential sale or wind-down","event_type":"other_material","sec_items":["7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063157","json":"https://secwatch.observer/filing/0001213900-26-063157.json","markdown":"https://secwatch.observer/filing/0001213900-26-063157.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1788028/000121390026063157/0001213900-26-063157-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1788028/000121390026063157/ea0292909-8k_jasper.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-249763","ticker":"JBIO","company_name":"Jade Biosciences, Inc.","filed_at":"2026-06-01T11:55:09+00:00","headline":"Jade Biosciences reports Phase 1 interim data: JADE101 shows ~70% IgA reduction, favorable safety, differentiated PK","event_type":"other_material","sec_items":["7.01","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-249763","json":"https://secwatch.observer/filing/0001193125-26-249763.json","markdown":"https://secwatch.observer/filing/0001193125-26-249763.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1798749/000119312526249763/0001193125-26-249763-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1798749/000119312526249763/d124589d8k.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-249725","ticker":"EIKN","company_name":"Eikon Therapeutics, Inc.","filed_at":"2026-06-01T11:30:25+00:00","headline":"Eikon reports 63.1% ORR in Phase 2 NSCLC trial of EIK1001; PARP1 inhibitor EIK1003 shows 24.5% ORR with paclitaxel","event_type":"other_material","sec_items":["7.01","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-249725","json":"https://secwatch.observer/filing/0001193125-26-249725.json","markdown":"https://secwatch.observer/filing/0001193125-26-249725.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526249725/0001193125-26-249725-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526249725/eikn-20260530.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}